Comparative Pharmacology
Head-to-head clinical analysis: KESSO GESIC versus PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KESSO GESIC versus PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN.
KESSO-GESIC vs PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KESSO-GESIC is a combination analgesic containing butalbital (barbiturate), acetaminophen, and caffeine. Butalbital depresses the CNS by enhancing GABA-A receptor activity, acetaminophen inhibits COX enzymes centrally, and caffeine is a CNS stimulant that may enhance analgesia.
Propoxyphene is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates central pain pathways.
Adults: 2 tablets (325 mg acetaminophen + 5 mg hydrocodone per tablet) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
One tablet (propoxyphene HCl 65 mg/acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum: 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 2–4 hours in healthy adults. In hepatic impairment, half-life may be prolonged up to 8 hours; in renal impairment, minimal change.
Propoxyphene: 6-12 h (prolonged in hepatic disease); Norpropoxyphene (active metabolite): 30-36 h (accumulation risk). Acetaminophen: 2-3 h (prolonged in hepatic disease).
Renal excretion of unchanged drug and metabolites: approximately 60% renal, 40% biliary/fecal. Major metabolites include glucuronide conjugates.
Renal: Propoxyphene ~20-25% as unchanged drug and metabolites; Acetaminophen ~85-90% as glucuronide and sulfate conjugates, <5% unchanged. Fecal: Minimal for both.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination